Pharmacogenomics and functional gastrointestinal disorders

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Functional gastrointestinal disorders, including irritable bowel syndrome and functional dyspepsia, are highly prevalent disorders affecting approximately one in four people in Western societies. This article reviews examples of the role of pharmacogenomics in the safety and efficacy of medications used in the management of such disorders. These include variations in the effects of medications metabolized by cytochrome P450 enzymes (e.g., 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome. These observations suggest that pharmacogenomics will introduce a new era in pharmacotherapeutics in gastroenterology.

Original languageEnglish (US)
Pages (from-to)491-501
Number of pages11
Issue number5
StatePublished - Jul 2005


  • Alosetron
  • CYP 450
  • Codeine
  • Diarrhea
  • Dyspepsia
  • GNβ3
  • Gastroenterology
  • Irritable bowel syndrome
  • Nortryptiline
  • SERT-P
  • Serotonergic antagonist

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Pharmacogenomics and functional gastrointestinal disorders'. Together they form a unique fingerprint.

Cite this